Pulse 探索 nav.journalClub 議論トレンド研究者ジャーナル

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

ホーム探索 nav.journalClub トレンド

⌘+K

Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome | Synapse

November 10, 2022Open Access

原発性シェーグレン症候群に対する低用量インターロイキン2の有効性と安全性

JHJing HeGuangxi University JCJiali ChenShenyang Pharmaceutical University MMMiao MiaoNanjing University of Chinese Medicine

Key Points

Key points are not available for this paper at this time.

Abstract

ClinicalTrials.gov識別子: NCT02464319.

AIに質問

Like

Bookmark

Share

View Full Paper

AIに質問

Like

Bookmark

Share

View Full Paper

Cite This Study

He et al. (Thu,) はこの問題を研究しました。

synapsesocial.com/papers/69d7cb9533ca018b39ae2dd4 https://doi.org/https://doi.org/10.1001/jamanetworkopen.2022.41451

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome2017 · 107 citations
2Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients2018 · 74 citations
3Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo2003 · 392 citations
4IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells2016 · 16 citations
5Circulating Precursor CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody Responses upon Antigen Reexposure2013 · 657 citations